Time to Peak Anti-Xa Activity for Fragmin (Dalteparin)
Fragmin (dalteparin) reaches peak anti-Xa activity approximately 4 hours after subcutaneous injection, with the maximum time being 5 hours. 1
Pharmacokinetic Profile
The FDA-approved drug label for Fragmin provides the most authoritative data on this question. Following subcutaneous administration of single doses ranging from 2,500 to 10,000 units, peak plasma anti-Xa activity was attained in about 4 hours in most subjects 1. This is consistent with the broader class characteristics of low molecular weight heparins (LMWHs).
Class-Wide LMWH Characteristics
The American College of Chest Physicians guidelines confirm that for the entire LMWH class, anti-Xa levels peak 3 to 5 hours after subcutaneous dosing 2. This range represents the expected window across different LMWHs, with dalteparin falling at the 4-hour mark within this spectrum.
Clinical Monitoring Implications
When anti-Xa monitoring is indicated (though not routinely necessary for most patients), the guidelines specifically recommend measuring peak anti-Xa levels 4 hours after dosing for dalteparin 2. This timing is critical for accurate assessment of anticoagulant effect.
Important Caveats
Renal impairment significantly delays elimination: In hemodialysis patients, the half-life extends to 5.7 ± 2.0 hours (compared to 2-3 hours in healthy volunteers), which may shift the time to peak activity 1
Subcutaneous absorption is the rate-limiting step: The apparent terminal half-life of 3-5 hours after subcutaneous dosing is longer than after IV administration due to delayed absorption 1
High bioavailability: Dalteparin has 87% ± 6% bioavailability after subcutaneous injection, ensuring predictable absorption 1
Practical Application
For clinical decision-making, if you need to assess peak anticoagulant effect:
- Draw anti-Xa levels at 4 hours post-injection for standard patients
- Consider the 3-5 hour window acceptable for sampling in most circumstances
- Extend monitoring time in renal failure patients where accumulation and delayed clearance occur
The predictable pharmacokinetics of dalteparin, with its consistent 4-hour peak time, is one of the advantages that allows fixed or weight-based dosing without routine monitoring in most clinical scenarios 2.